PTK7 and neoplasm: Nevertheless, tumor volumes were significantly reduced to 68.8 ± 5.3% by PTK7 mAb-32 and to 61 ± 7.7% by PTK7 mAb-43, compared with that of the vehicle group (Figure 6A).